IMS Health Holdings Inc. (IMS, Financial) reached the 52-week high of $31.34
IMS Health Holdings Inc. was formed on Oct. 23, 2009, in Delaware. The company is an information and technology services company. It provides clients in the health care industry with comprehensive solutions to measure and improve their performance. It has collections of health care information, spanning sales, prescription and promotional data, medical claims, electronic medical records and social media. The company provides service to health care organizations and decision makers around the world, spanning the breadth of life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
The price of IMS Health Holdings Inc. shares has reached $31.34, which is 0.8% off the 52-week high of $31.59. IMS Health Holdings Inc. has a market cap of $10.32 billion; its shares were traded around $31.34 .
IMS Holdings Inc. recently reported financial results for the quarter ended Sept. 30, 2017. Revenue for the third quarter of $2.02 billion increased 4.8% on a reported basis, and 4.3% on a constant currency basis, compared to the third quarter of 2016. Third-quarter 2017 adjusted EBITDA was $512 million. GAAP net income was $84 million and GAAP diluted earnings per share were 38 cents. Adjusted net income was $260 million and adjusted diluted earnings per share were $1.19.
Liberty SiriusXM Group (LSXMB, Financial) reached the 52-week high of $47.61
Liberty SiriusXM Group through its subsidiary holding is engaged in providing a subscription-based satellite radio service. It transmits music, sports, entertainment, comedy, talk, news, traffic and weather channels, as well as infotainment services. The company distributes its satellite radios through automakers and rental car companies, as well as through its retail locations and Website; and satellite radio services to various automaker customers. Geographically it offers services in the region of U.S. and Canada.
The price of Liberty SiriusXM Group shares has reached $47.61, which is 0.0% off the 52-week high of $47.61. Liberty Siriusxm Group has a market cap of $13.72 billion; its shares were traded around $47.61 with a P/E ratio of 24.37 and P/S ratio of 3.06.
Liberty Media Corporation recently reported third quarter 2017 results. Third quarter revenue climbed 8% to $1.4 billion. Quarterly net income increased 42% to $276 million. Diluted earnings per share grew 49% to $0.06. Adjusted EBITDA grew 12% to a quarterly record of $551 million and margin of 39.9%. Quarterly operating cash flow rose 24% to $521 million.
Kite Pharma Inc. (KITE, Financial) reached the 52-week high of $179.79
Kite Pharma Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.
The price of Kite Pharma Inc. shares has reached $179.79, which is 0.1% off the 52-week high of $179.95. Kite Pharma Inc. has a market cap of $10.31 billion; its shares were traded around $179.79 with and P/S ratio of 292.34.
Kite Pharma Inc. (KITE, Financial) recently reported second quarter 2017 financial results and provided a corporate update for the period ended June 30, 2017. Revenue was $10.1 million for the second quarter of 2017. Research and development expenses were $70.9 million for the second quarter of 2017, including $13.1 million of non-cash stock-based compensation expense. General and administrative expenses were $41.1 million for the second quarter of 2017, including $12.1 million of non-cash stock-based compensation expense. Net loss was $109.8 million, or $1.94 per share, for the second quarter of 2017. Non-GAAP net loss for the second quarter of 2017 was $84.7 million, or $1.50 per share, excluding non-cash stock-based compensation expense of $25.2 million.
Agrium Inc. (AGU, Financial) reached the 52-week high of $115.00
Agrium Inc. is a retail supplier of agricultural products and services in North and South America and producer and marketer of agricultural nutrients and industrial products. With more than 1,400 retail centers, Canada-based Agrium is the largest agricultural retailer in the U.S., selling fertilizers, crop chemicals and seed directly to farm customers. The company's wholesale business produces and markets the three main crop nutrients -- nitrogen, potash, and phosphate -- with natural resources located mainly in Canada and the U.S. The bulk of Agrium's sales are generated in the U.S., Canada and Australia.
The price of Agrium Inc. shares has reached $115.00, which is -1.5% off the 52-week high of $113.25. Agrium Inc. has a market cap of $15.84 billion; its shares were traded around $115.00 with a P/E ratio of 39.72 and P/S ratio of 1.09. The trailing 12-month dividend yield of Agrium Inc. stocks is 3.04%. The forward dividend yield of Agrium Inc. stocks is 3.04%. Agrium Inc. had an annual average earnings growth of 16.10% over the past 10 years.
Agrium Inc. announced its 2017 third quarter results, with a net loss from continuing operations of $69 million (52 cents diluted loss per share) compared to a net loss from continuing operations of $38 million (28 cents diluted loss per share) in the third quarter of 2016. The third quarter results were driven by lower overall sales volumes and higher cost of product sold related to several scheduled maintenance turnarounds and higher share-based payments due to a year-to-date total shareholder return of 10% at Sept. 30.
Bioverativ Inc. (BIVV, Financial) reached the 52-week high of $103.05
Bioverativ Inc. is a global biotechnology company which focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
The price of Bioverativ Inc. shares has reached $103.05, which is 1.2% off the 52-week high of $104.30. Bioverativ Inc. has a market cap of $11.15 billion; its shares were traded around $103.05 with a P/E ratio of 21.95 and P/S ratio of 10.18.
Bioverativ Inc. reported financial results for the third quarter of 2017. Third quarter 2017 revenue was $291.6 million, up 27.2% year-over-year. Third quarter 2017 GAAP net income was down 15.7% year-over-year. Non-GAAP net income was up 32.8% year-over-year. Third quarter 2017 GAAP earnings per share were 63 cents, down 16.0% year-over-year. Non-GAAP earnings per share were 80 cents, up 31.1% year-over-year. The company generated cash flows from operations of $377.6 million for the nine months ended Sept. 30, 2017.
Note: I do not own the stocks discussed in this article.
